Evolution of Humoral and Cellular Immunity Post–Breakthrough Coronavirus Disease 2019 in Vaccinated Patients With Hematologic Malignancy Receiving Tixagevimab-Cilgavimab.

Autor: Hall, Victoria G1,2,3 (AUTHOR) victoria.hall@petermac.org, Nguyen, Thi H O3 (AUTHOR), Allen, Lilith F3 (AUTHOR), Rowntree, Louise C3 (AUTHOR), Kedzierski, Lukasz3 (AUTHOR), Chua, Brendon Y3,4 (AUTHOR), Lim, Chhay1 (AUTHOR), Saunders, Natalie R1 (AUTHOR), Klimevski, Emily1 (AUTHOR), Tennakoon, Gayani S1 (AUTHOR), Seymour, John F2,5 (AUTHOR), Wadhwa, Vikas6 (AUTHOR), Cain, Natalie7 (AUTHOR), Vo, Kim L7 (AUTHOR), Nicholson, Suellen7 (AUTHOR), Karapanagiotidis, Theo7 (AUTHOR), Williamson, Deborah A7 (AUTHOR), Thursky, Karin A1,2 (AUTHOR), Spelman, Timothy8,9 (AUTHOR), Yong, Michelle K1,2 (AUTHOR)
Zdroj: Open Forum Infectious Diseases. Nov2023, Vol. 10 Issue 11, p1-12. 12p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje